Novo Nordisk A/S Release: Data Show That the Combination of Insulin Degludec/Insulin Aspart Significantly Reduced Hypoglycaemia in Type 1 and Type 2 Diabetes Patients

DUBAI, United Arab Emirates--(BUSINESS WIRE)--A soluble co-formulation of insulin degludec and insulin aspart (IDegAsp) was associated with a 58% lower rate of confirmed hypoglycaemic episodes in people with type 2 diabetes compared to biphasic insulin aspart 30 (BIAsp 30) when dosed twice-daily. This is according to a study released today by Novo Nordisk at the International Diabetes Federation (IDF) 21st World Diabetes Congress.